文献速递肾小球疾病慢性肾脏病

肾小球Exostosin阳性与膜性狼疮肾炎疾病活动度及结局相关

Glomerular Exostosin-Positivity is Associated With Disease Activity and Outcomes in Patients With Membranous Lupus Nephritis.
PubMed 文献 · Kidney Int Rep · 2024-01-10

该研究对283例连续膜性狼疮肾炎(MLN)患者行EXT1/EXT2免疫组化,比较阳性与阴性患者的临床病理特征及结局。29.3%患者EXT1/EXT2阳性,纯V型MLN阳性率高于混合型(44.2% vs 19.4%,P<0.001)。中位随访65个月,EXT1/EXT2阳性患者不良肾脏事件更少(2.4% vs 16.0%,P=0.001),且疾病活动度和慢性化指标更低。

要点

  • EXT1/EXT2阳性见于29.3%的MLN患者,纯V型阳性率高于混合型。
  • EXT1/EXT2阳性患者SLEDAI评分和血肌酐更低,血红蛋白更高。
  • EXT1/EXT2阳性与更少不良肾脏事件相关(2.4% vs 16.0%)。

核心结论

  • EXT1/EXT2阳性MLN患者疾病活动度更低,且不良肾脏事件风险更低。

研究设计与样本

  • 回顾性队列研究,纳入283例连续MLN患者,行EXT1/EXT2免疫组化检测。

主要发现

  • EXT1/EXT2阳性率为29.3%,纯V型MLN阳性率44.2%高于混合型19.4%(P<0.001)。
  • EXT1/EXT2阳性患者狼疮起病至肾活检中位时间6个月(IQR 2-25)短于阴性12个月(IQR 3-49)(P=0.008)。
  • EXT1/EXT2阳性患者狼疮肾炎起病至肾活检中位时间3个月(IQR 2-18)短于阴性6个月(IQR 2-23)(P=0.039)。
  • EXT1/EXT2阳性患者SLEDAI评分更低(P=0.015)、血肌酐更低(P<0.001)、血红蛋白更高(P=0.006)且血压更低。
  • EXT1/EXT2阳性患者肾活检慢性化指标(肾小球硬化P<0.001、间质纤维化P=0.006、肾小管萎缩P=0.002)和活动指标(内皮细胞增生P=0.012、细胞性新月体P=0.007、纤维细胞性新月体P<0.001)更少。

关键数值与推荐

  • 中位随访65个月(IQR 28-126),EXT1/EXT2阳性患者不良肾脏事件(死亡、透析、肾移植)发生率2.4%低于阴性16.0%(P=0.001)。

临床怎么用

  • 对MLN患者行EXT1/EXT2免疫组化检测,有助于识别疾病活动度和慢性化程度较低、预后较好的亚群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The relationship of exostosin 1 and exostosin 2 (EXT1/EXT2) expression and outcomes in membranous lupus nephritis (MLN) was controversial. METHODS: EXT1/EXT2 was performed by immunohistochemistry (IHC) in 283 consecutive patients with MLN. Clinicopathological characteristics and outcomes of EXT1/EXT2-positive patients were compared with EXT1/EXT2-negative patients. The primary end points were adverse renal events, including death, dialysis, and renal transplantation. RESULTS: Of the patients with MLN, 29.3% were positive for EXT1/EXT2. The prevalence of EXT1/2-positive MLN was significantly higher in pure class V MLN than those for mixed class V MLN (44.2% vs. 19.4%, P < 0.001). For EXT1/EXT2-positive patients, the median time between onset of lupus and renal biopsy, and lupus nephritis and renal biopsy is shorter (6 [interquartile range, IQR: 2-25] months vs. 12 [IQR: 3-49] months, P = 0.008 and 3 [IQR: 2-18] months vs. 6 [IQR: 2-23] months, P = 0.039) and they had significantly lower systemic lupus erythematosus Disease Activity Index (SLEDAI) scores (P = 0.015) and lower serum creatinine levels (P < 0.001), higher hemoglobin (P = 0.006) as well as lower blood pressure. The EXT1/EXT2-positive patients had significantly fewer chronicity features (glomerulosclerosis, P < 0.001; interstitial fibrosis, P = 0.006; and tubular atrophy, P = 0.002) and fewer activity indicators (endocapillary hypercellularity, P = 0.012; cellular crescents, P = 0.007; and fibrocellular crescents, P < 0.001) on renal biopsy. After a median follow-up of 65 (28-126) months, EXT1/EXT2-positive patients were less likely to experience adverse renal events (2.4% vs. 16.0%, P = 0.001). CONCLUSION: Compared with EXT1/EXT2-negative patients, the EXT1/EXT2-positive patients presented with lower disease activity and were less likely to experience adverse renal events in relationship with the chronicity index.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Xia X, Li S, Wang Z, et al. Glomerular Exostosin-Positivity is Associated With Disease Activity and Outcomes in Patients With Membranous Lupus Nephritis. Kidney Int Rep. 2024. PMID: 38765564. doi:10.1016/j.ekir.2024.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。